%PDF-1.4
%
165 0 obj
<>
endobj
162 0 obj
<>
endobj
208 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-02-28T18:42:53Z
2024-03-28T04:18:13-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T04:18:13-07:00
application/pdf
Heather
2003-975.may
uuid:f1b0204f-1dd1-11b2-0a00-270a275d6100
uuid:f1b02051-1dd1-11b2-0a00-aa0000000000
endstream
endobj
151 0 obj
<>
endobj
152 0 obj
<>
endobj
166 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 129 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 131 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 133 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 135 0 R/Type/Page>>
endobj
34 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 137 0 R/Type/Page>>
endobj
53 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 139 0 R/Type/Page>>
endobj
72 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 141 0 R/Type/Page>>
endobj
83 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 143 0 R/Type/Page>>
endobj
118 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 145 0 R/Type/Page>>
endobj
242 0 obj
[246 0 R]
endobj
243 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 53.8216 56.7343 Tm
(664)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:4)Tj
ET
0 0 0 0 k
/GS0 gs
102.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
102.631 81.583 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 73.868 737.0293 Tm
(stimulates alpha 2\(I\) collagen gene expression through a cis-acting)Tj
0 -1.25 TD
(element that contains an Sp1-binding site. J Biol Chem)Tj
0 Tc 0 Tw T*
(1994;269:14828-34.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Riccio )54.8 (A, De Caterina M, Natale D, et al. Serum levels of)]TJ
2.1381 -1.25 Td
(granulocyte macrophage-colony stimulating factor \(GM-CSF\) in a)Tj
T*
(group of patients with systemic sclerosis. Int J Immunopathol)Tj
T*
(Pharmacol 1996;9:9-12.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Dedhar S, Gaboury L, Galloway P)110.7 (, Eaves C. Human GM-CSF is a)]TJ
2.175 -1.25 Td
(growth factor active on variety of cell types of non-hemopoietic)Tj
T*
[(origin. Proc Natl )54.8 (Acad Sci USA. 1988;85:9253-7. )]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Metcalf D. )17.7 (The GM-CSF)79.7 (. Science 1985;229:16-23.)]TJ
T*
[(14.)-875.1 (Aglietta M, Monzeglio C, Sanavio F)79.7 (, et al. In vivo ef)17.7 (fect of human)]TJ
2.175 -1.25 Td
[(GM-CSF on megakaryocytopoiesis. Blood 1991;77:1)36.8 (191-4.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Gasson JC. Molecular physiology of GM-CSF)79.7 (. Blood)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
[(1991;77:1)36.9 (131-9.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Bussolino F)79.7 (, Ziche X, Ming )17.7 (W)79.9 (ang J, et al. In vitro and in vivo)]TJ
2.175 -1.25 Td
(activation of endothelial cells by colony stimulating factors. J Clin)Tj
T*
(Invest 1991;87:986-93.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Lang RA, Cuthbertson RA, Kelso )54.8 (A, et al. )17.7 (T)35 (ransgenic mice)]TJ
2.175 -1.25 Td
(expressing a hematopoietic growth factor gene \(GM-CSF\) develop)Tj
T*
(accumulation of macrophages, blindness, and a fatal syndrome of)Tj
T*
(tissue damage. Cell 1997;51:675-88.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Postiglione L, Montagnani S, Riccio )54.8 (A, et al. Enhanced expression)]TJ
2.175 -1.25 Td
(of the receptor for granulocyte macrophage-colony stimulating)Tj
T*
(factor on dermal fibroblasts from scleroderma patients. )Tj
T*
(J Rheumatol 2002;29:94-101.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Colotta F)79.7 (,)-0.1 ( Bussolino F)79.7 (, Polentarutti N, et al. Dif)17.7 (ferential expression)]TJ
2.175 -1.25 Td
(of the common \247 and specific )Tj
/T1_2 1 Tf
0 Tc 0 Tw 12.2567 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 0.9059 0 Td
(chains of the receptors for GM-)Tj
-13.1626 -1.25 Td
[(CSF)79.7 (, IL3 and IL5 endothelial cells. Cell Res 1993;206:31)36.8 (1-20.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Steen )17.7 (VD, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (, Rodnan GP)110.7 (. D-Penicillamine therapy in)]TJ
2.175 -1.25 Td
(progressive systemic sclerosis \(scleroderma\): a retrospective)Tj
T*
[(analysis. )54.8 (Ann Intern Med 1982;97:652-9.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Liu )17.7 (T)74 (, Dhanasekaran SM, Jin H, et al. FIZZ 1 stimulation of)]TJ
2.175 -1.25 Td
[(myofibroblast dif)17.7 (ferentiation. )54.8 (Am J Pathol 2004;164:1315-26.)]TJ
-2.175 -1.25 Td
[(22.)-875.1 (Jelaska )54.8 (A, )54.8 (Arakawa M, Broketa G, Korn JH. Heterogeneity of)]TJ
2.175 -1.25 Td
(collagen synthesis in normal and systemic sclerosis skin fibroblasts.)Tj
T*
(Increased proportion of high collagen-producing cells in systemic)Tj
T*
[(sclerosis fibroblasts. )54.8 (Arthritis Rheum 1996;39:1338-46.)]TJ
-2.175 -1.25 Td
[(23.)-875.1 (Higley H, Persichitte K, Chu S, )17.7 (W)79.9 (aegell )17.7 (W)91.9 (,)-0.1 ( )17.7 (V)110.8 (ancheeswaran R,)]TJ
2.175 -1.25 Td
(Black C. Immunocytochemical localization and serologic detection)Tj
T*
[(of transforming growth factor \2471. )54.8 (Association with type I)]TJ
T*
[(procollagen and inflammatory cell markers in dif)17.7 (fuse and limited)]TJ
T*
[(systemic sclerosis, morphea, and Raynaud\325)54.8 (s phenomenon. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1994;37:278-88.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875.1 (Y)99.8 (a)-0.1 (mane K, Ihn H, Kubo M, )17.7 (T)69.9 (amaki K. Increased transcriptional)]TJ
2.175 -1.25 Td
(activities of transforming growth factor beta receptors in)Tj
T*
[(scleroderma fibroblasts. )54.8 (Arthritis Rheum 2002;46:2421-8.)]TJ
30.825 57.5 Td
[(25.)-875.1 (Postiglione L, Montagnani S, Riccio )54.8 (A, et al. Expression of GM-)]TJ
2.175 -1.25 Td
[(CSF receptor and \322in vitro\323 ef)17.7 (fects of GM-CSF on human)]TJ
T*
(fibroblasts. Life Sci 1998;63:327-36.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (Reitamo S, Remitz )54.8 (A, )17.7 (T)69.9 (amai K, Uitto J. Interleukin\32010 modulates)]TJ
2.175 -1.25 Td
(type I collagen and matrix metalloprotease gene expression in)Tj
T*
(cultured human skin fibroblasts. J Clin Invest 1994;94:2489-92.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Rosenbloom J, Feldman G, Freundlich B, Jimenez SA. Inhibition of)]TJ
2.175 -1.25 Td
(excessive scleroderma fibroblast collagen production by)Tj
T*
[(recombinant gamma-interferon. )54.8 (Association with a coordinate)]TJ
T*
[(decrease in types I and III procollagen messenger RNA)-220.2 (levels.)]TJ
T*
(Arthritis Rheum 1986;29:851-6.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (T)69.9 (akeda K, Hatamochi )54.8 (A, Ueki H, Nakata M, Oishi )36.7 (Y)128.9 (. Decreased)]TJ
2.175 -1.25 Td
(collagenase expression in cultured systemic sclerosis fibroblasts. )Tj
T*
(J Invest Dermatol 1994;103:359-63.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Kuroda K, Shinkai H. Gene expression of types I and III collagen,)]TJ
2.175 -1.25 Td
(decorin, matrix metalloproteinases and tissue inhibitors of)Tj
T*
(metalloproteinases in skin fibroblasts from patients with systemic)Tj
T*
[(sclerosis. )54.8 (Arch Dermatol Res 1997;289:567-72.)]TJ
-2.175 -1.25 Td
[(30.)-875.1 (Kuroda K, )17.7 (T)69.9 (sukifuji R, Shinkai H. Increased expression of heat-)]TJ
2.175 -1.25 Td
(shock protein 47 is associated with overproduction of type I)Tj
T*
(procollagen in systemic sclerosis skin fibroblasts. J Invest Dermatol)Tj
0 Tc 0 Tw T*
[(1998;1)36.9 (1)36.9 (1:1023-8.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (Asano )36.8 (Y)128.9 (,)-0.1 ( Ihn H, )36.8 (Y)99.8 (amane K, Kubo M, )17.7 (T)69.9 (amaki K. Impaired Smad7-)]TJ
2.175 -1.25 Td
[(Smurf-mediated negative regulation of )17.7 (TGF-\247 signaling in)]TJ
T*
[(scleroderma fibroblasts. J Clin Invest 2004;1)36.8 (13:253-64. )]TJ
-2.175 -1.25 Td
[(32.)-875.1 (Holmes )54.8 (A, )54.8 (Abraham DJ, Sa S, Shiwen X, Black CM, Leask )54.8 (A.)]TJ
2.175 -1.25 Td
(CTGF and SMADs, maintenance of scleroderma phenotype is)Tj
T*
(independent of SMAD signaling. J Biol Chem 2001;14:10594-601.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (Mori )36.8 (Y)128.9 (,)-0.1 ( Chen SJ, )17.7 (V)110.8 (a)0.3 (r)17.7 (ga J. Expression and regulation of intracellular)]TJ
2.175 -1.25 Td
[(SMAD signaling in scleroderma skin fibroblasts. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2003;48:1964-78.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(34.)-875.1 (T)69.9 (akagawa S, Lakos G, Mori )36.8 (Y)128.9 (,)-0.1 ( )36.8 (Y)99.8 (amamoto )17.7 (T)74 (, Nishioka K, )17.7 (V)110.8 (a)0.3 (r)17.7 (ga J.)]TJ
2.175 -1.25 Td
[(Sustained activation of fibroblast transforming growth factor)19.7 (-)]TJ
T*
(\247/Smad signaling in a murine model of scleroderma. J Invest)Tj
T*
(Dermatol 2003;121\):41-50.)Tj
-2.175 -1.25 Td
[(35.)-875.1 (Ghosh )54.8 (AK. Factors involved in the regulation of type I collagen)]TJ
2.175 -1.25 Td
(gene expression: implication in fibrosis. Exp Biol Med \(Maywood\))Tj
0 Tc 0 Tw T*
(2002;227:301-14.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(36.)-875.1 (Asano )36.8 (Y)128.9 (,)-0.1 ( Ihn H, )36.8 (Y)99.8 (amane K, Kubo M, )17.7 (T)69.9 (amaki K. Increased)]TJ
2.175 -1.25 Td
(expression levels of integrin )Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.5 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (v\2475 on scleroderma fibroblasts. )54.8 (Am J)]TJ
0 Tc 0.0001 -1.25 Td
(Pathol 2004;164:1275-92.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(37.)-875.1 (Jor)17.7 (gensen LN, )54.8 (Agren MS, Madsen SM, et al. Dose-dependent)]TJ
2.175 -1.25 Td
(impairment of collagen deposition by topical granulocyte)Tj
T*
(macrophage colony stimulating factor in human experimental)Tj
0 Tc -0.02991 Tw T*
[(wounds. Ann )-54.8 (Sur)17.8 (g )-54.9 (2002;236:684-92.)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
145 0 obj
<>stream
8;Z\7;3p5r#h/`*aE;Z=&gS'!VpfARA"WF_Gth!e(*G@E)ug]SHsM7%n<`UiEIY(0
Z&J.:YFjga)12V9'&^[A=.F`T.iLXm`Wm9!45N$qO)Z6,#b*p1.<2Mdj^F9Qk:i'<
4Xb6">a[Ao?^@Z.dtGqP.&rk"Kt\ZqkrfKDr.dNm)K-3Wktm5',d9S;XqV&(
pWMR'?EZ_5Et9%Q_#l!=_2m
QBt(h0*1)^HqWoI9j!&ES\4+KWNR8@g_B]F`Z>sk8,5$!a3t'
b+M&+FGYGl,o;aM<'t3VgMit8U@Ar:($>is_M.0Y=`_s2ap8cHD>-p=I2[RU@=R
l+H95OO0,Ld0?a89kCu]
endstream
endobj
149 0 obj
[/Indexed/DeviceRGB 255 148 0 R]
endobj
148 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
170 0 obj
<>
endobj
172 0 obj
<>
endobj
122 0 obj
<>
endobj
189 0 obj
<>
endobj
213 0 obj
<>
endobj
127 0 obj
<>
endobj
125 0 obj
<>
endobj
128 0 obj
<>stream
HT=o0w~ǫ: e80CHG0zRDZ_}i>U=v
aYF%UKn_.,u>cr
~K/?O^._'ns 9H #Nk^{/gilhG\]fFs.TЌsYuTO"')n@QJ%2.\ \@uO1D!y&dL|YG>d uy
endstream
endobj
126 0 obj
<>stream
H,[HSq]Qq&vzH4Dn)d̎z96;~ۦ[sմ̬!C{AG(g=><|0~ ^TY&U3(CG "C7|D$q
neCz{1Q! vْ`B Ri[ia(mIד*IҚR&͑AO$rNeǘǂdDa"*LR1ąN֑z6
i[`P:î_aB"8Y0w@7&ڭ0v
+I%-<̃^I-JJzznWuڭ!Xr?2n%"EG(k#)O~*n&-Jt,Z*|}.
EJ۹v?ߘm2+_Cޏ:|zc}3k&!ki2hZ뷍g,P7ҹ:դQ[Ns:e|#d[^x:ݮ5s3uj~rU@֔A'<^QpcfFۆj5GuråẔKMiD[1B;xQYU|fFd3B{_P&R$QBPGwBY^S1#1&8[8 4!
endstream
endobj
171 0 obj
<>
endobj
181 0 obj
<>stream
H|T PTW7"ҟ[oh7%*1`[1@ tӍ
,B˒DYD,B+2(!jTaX\ЌR~0Fj2Uԫw߫[ܺw x㤷F?Xn&u2nʽblsqsprCqŎ`ߌwJ3Ϧ}mqSmr%rjM6*"2AQDzΫ?Y4eWSY.SdɺUNjZe*lL#4A'ۤҩzm(L)K*TJn:\S'$kT2u2e\Z+2t{BtQaQJmJ2^_6&0
a\S,
að+ðJlfcvθg[y
Nt' OZ7
M;&wcNK6ff;]0w5ViV#r36MMI"9,$.}Czuؽu~f9 C*7r:ldlL,s JȺZu@|=y1cb!'vi8X8-M7El_]_uBV ?Ra!U-e),[FyJjN)\?y Apk_[S(iv6Tհy.43*,C*-%{(0c/ҕ8/A`a`ZI?5EYaG=e }-닋̤/|X7:oʇrrrB߬ex])=f nK_g`S9Eؘ}{Xp#RϣQBwO?F9IZdɓD]
T{I]4'qX__StlS`4v41"(O+bL겟bQq.fEiUeiu6x}CynN_rzѕ'鲬xC1UB:w~!
fU.M
ZzPÇhHP 5h|bV% o%9Y&O8lV(-X|`aLSZnUsJ5+v+Ox'
Λ^xBqj}eP8P`[sCdl ao[^J,uJ ( R H[e
vX!HpB''~YT
mC[